Astrazeneca Plc ADR (AZN)

$193.03 +5.87 (3.14%)
Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
HedgeFollow
HedgeFollow May. 13 at 5:11 PM
🔍 𝗝𝗣𝗺𝗼𝗿𝗴𝗮𝗻 13𝗙 𝗶𝘀 𝗢𝗨𝗧 🔎 Most notable position changes: 𝗔𝗱𝗱𝗲𝗱 60% 𝗺𝗼𝗿𝗲: $PG 𝗛𝗲𝗮𝘃𝗶𝗹𝘆 BOOSTED: $DG, $AZN 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 50%: $HOOD, $SHOP Procter & Gamble, Dollar General & Astrazeneca are good picks. JPmorgan is up 77% in the past 3 years Source: https://hedgefollow.com/funds/Jpmorgan+Chase+-And-+Co
0 · Reply
Charlie_Omaha
Charlie_Omaha May. 13 at 3:55 PM
$IOVA If any, Trump policies of Made in USA and Most Favored Nation rules make this an attractive candidate for $AZN $NVS $TAK as it counts as US plant and manufacturing, and accumulated debt as tax savings. Fred and Wayne are idiots.
0 · Reply
LandonCapital
LandonCapital May. 12 at 6:22 PM
$AZN https://landoncapital.net/meeting-the-standard-astrazeneca-drug-meets-primary-endpoint-in-rare-disease-trial/
0 · Reply
ApexEquityVault
ApexEquityVault May. 12 at 3:51 PM
High Confidence 🚨 $AZN 210 Call 6/18 at 0.65
0 · Reply
ApexEquityVault
ApexEquityVault May. 12 at 3:51 PM
$AZN 210 Call 6/18 at 0.65
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial May. 12 at 3:49 PM
$AZN 210 CALL 6/18 @ .65
0 · Reply
HedgeFollow
HedgeFollow May. 11 at 10:23 PM
🔍 𝗣𝗿𝗶𝗺𝗲𝗰𝗮𝗽 13𝗙 𝗷𝘂𝘀𝘁 𝗿𝗲𝗹𝗲𝗮𝘀𝗲𝗱! 🔎 Most notable trades Theofanis made last quarter: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 𝗕𝘂𝘆𝘀: $GTLB & $BA 𝗔𝗱𝗱𝗲𝗱 30-40% 𝗺𝗼𝗿𝗲: $ADBE & $ERIC 𝗥𝗲𝗱𝘂𝗰𝗲𝗱: $AZN 𝗦𝗢𝗟𝗗 𝗼𝘂𝘁: CRCL Theo's portfolio is up 92% in the past 3 years. Source: https://hedgefollow.com/funds/Primecap+Management
0 · Reply
biolover
biolover May. 11 at 2:40 PM
$VKTX $AZN had data on $LLY orfor copy in late 2025. Not promising when u wait 7 months and u are are a copy of already optimized but weak drug. AZN does not have anything competitive in obesity. The deal in China is all preclinical. Good luck. Management is preoccupied with combining oral GLP1 with fading farxiga But dont u need a molecule that works as a first step?
1 · Reply
Estimize
Estimize May. 11 at 12:06 PM
Wall St is expecting 2.49 EPS for $AZN Q2 [Reporting 07/27 BMO] http://www.estimize.com/intro/azn?chart=historical&metric_name=eps&utm_cont
0 · Reply
Quantumup
Quantumup May. 11 at 10:49 AM
Oppenheimer⬇️ $CRNX's PT to $84 from $87, reiterated at Outperform, and said: CRNX posted $10.7M in total revenue, above our/cons estimates of $7.0M/$8.5M as Palsonify's launch gathers steam. $AZN PFE $NVS IPSEY NBIS SPRB XERS Oppenheimer added—Phase 3 trial in carcinoid syndrome continues its enrollment, and atumelnant is moving along in its respective pivotal and Phase 2 trials in adult and pediatric CAH with a Phase 2/3 to soon begin in ACTH-dependent Cushing syndrome. We have our eye on CRN09682's initial clinical reveal in neuroendocrine tumors, which we believe will come toward year-end. Cash runway into 2030. Current levels may reflect a relative paucity of upcoming catalysts, but we believe today's buyers will be rewarded as CRNX's growing endocrine portfolio marks commercial and clinical success.
0 · Reply
Latest News on AZN
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Wed, 13 May 2026 01:00:00 -0400 - 14 hours ago

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

AstraZeneca (AZN) Reflects on Changes in FDA Leadership

2026-05-12T21:39:11.000Z - 21 hours ago

AstraZeneca (AZN) Reflects on Changes in FDA Leadership

AstraZeneca (AZN) Reports Positive CALYPSO Phase III Trial Results

2026-05-12T14:31:26.000Z - 1 day ago

AstraZeneca (AZN) Reports Positive CALYPSO Phase III Trial Results

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Tue, 12 May 2026 09:45:00 -0400 - 1 day ago

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

AstraZeneca says CALYPSO Phase III trial met composite primary endpoint

2026-05-12T12:49:22.000Z - 1 day ago

AstraZeneca says CALYPSO Phase III trial met composite primary endpoint

AstraZeneca's Ongoing Vaccine Debate Amid Health Secretary's Quest for Evidence

2026-05-11T23:51:45.000Z - 1 day ago

AstraZeneca's Ongoing Vaccine Debate Amid Health Secretary's Quest for Evidence

PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact

2026-05-11T22:00:25.000Z - 1 day ago

PRIMECAP Management's Strategic Moves: AstraZeneca PLC Exits with a -2.57% Impact

How AstraZeneca Plans to Hit $80 Billion in Revenue and Expand in the U.S.

2026-05-11T09:30:00.000Z - 2 days ago

How AstraZeneca Plans to Hit $80 Billion in Revenue and Expand in the U.S.

IRW-News: ACCESS Newswire: AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo(TM) 2 …

2026-05-07T12:09:01.000Z - 6 days ago

IRW-News: ACCESS Newswire: AstraZeneca und OMP demonstrieren auf dem Gartner Supply Chain Symposium/Xpo(TM) 2 …

CDT Equity announces AZD5904 progresses into patent cooperation treaty phase

2026-05-07T04:50:30.000Z - 6 days ago

CDT Equity announces AZD5904 progresses into patent cooperation treaty phase

AZN CDT

Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions

2026-05-06T23:07:07.000Z - 6 days ago

Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio Additions

What does AstraZeneca's £300m investment mean for Cambridge?

2026-05-02T05:27:06.000Z - 11 days ago

What does AstraZeneca's £300m investment mean for Cambridge?

AstraZeneca Faces Setback as FDA Advisory Panel Rejects Cancer Drug (AZN)

2026-05-01T17:42:17.000Z - 12 days ago

AstraZeneca Faces Setback as FDA Advisory Panel Rejects Cancer Drug (AZN)

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

Fri, 01 May 2026 08:20:14 -0400 - 12 days ago

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

AstraZeneca stock falls after FDA panel votes against new cancer drug

Fri, 01 May 2026 05:51:15 -0400 - 12 days ago

AstraZeneca stock falls after FDA panel votes against new cancer drug

ODAC recommends AstraZeneca Truqap for hormone-sensitive prostate cancer

2026-05-01T09:32:22.000Z - 12 days ago

ODAC recommends AstraZeneca Truqap for hormone-sensitive prostate cancer

AZN

AstraZeneca: FDA Panel Recommends Truqap Combination For PTEN-Deficient Prostate Cancer

2026-05-01T08:59:48.000Z - 12 days ago

AstraZeneca: FDA Panel Recommends Truqap Combination For PTEN-Deficient Prostate Cancer

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

Fri, 01 May 2026 03:56:00 -0400 - 12 days ago

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

Fri, 01 May 2026 03:09:11 -0400 - 12 days ago

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

AstraZeneca: Advisory Committee Recognises Favourable Benefit Risk Profile For Truqap Combination

2026-05-01T04:12:00.000Z - 12 days ago

AstraZeneca: Advisory Committee Recognises Favourable Benefit Risk Profile For Truqap Combination

TRUQAP (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

2026-05-01T01:42:00.000Z - 12 days ago

TRUQAP (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

AstraZeneca (AZN) Receives Positive FDA Advisory for Truqap in Prostate Cancer Treatment

2026-04-30T23:27:53.000Z - 12 days ago

AstraZeneca (AZN) Receives Positive FDA Advisory for Truqap in Prostate Cancer Treatment

AstraZeneca says FDA AdCom recommend Truqap in mHSPC

2026-04-30T22:01:07.000Z - 12 days ago

AstraZeneca says FDA AdCom recommend Truqap in mHSPC

AZN

AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant

2026-04-30T21:25:49.000Z - 12 days ago

AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant

AstraZeneca (AZN) Faces Setback, But Analyst Stays Bullish

2026-04-30T20:54:39.000Z - 12 days ago

AstraZeneca (AZN) Faces Setback, But Analyst Stays Bullish

AstraZeneca to ‘continue to work with FDA’ after vote against camizestrant

2026-04-30T19:44:25.000Z - 12 days ago

AstraZeneca to ‘continue to work with FDA’ after vote against camizestrant

AZN

Jefferies says ODAC vote against AstraZeneca’s SERENA-6 not a surprise

2026-04-30T19:31:45.000Z - 12 days ago

Jefferies says ODAC vote against AstraZeneca’s SERENA-6 not a surprise

AZN

AstraZeneca (AZN) Faces Setback as FDA Panel Rejects Breast Cancer Drug

2026-04-30T19:27:16.000Z - 12 days ago

AstraZeneca (AZN) Faces Setback as FDA Panel Rejects Breast Cancer Drug

AstraZeneca (AZN) Faces Setback as FDA Advisory Panel Questions Drug's Benefit

2026-04-30T18:59:15.000Z - 13 days ago

AstraZeneca (AZN) Faces Setback as FDA Advisory Panel Questions Drug's Benefit

FDA panel votes 6-3 to reject AstraZeneca breast cancer drug, Bloomberg says

2026-04-30T18:16:41.000Z - 13 days ago

FDA panel votes 6-3 to reject AstraZeneca breast cancer drug, Bloomberg says

AZN

Guardant falls after FDA panel votes down AstraZeneca breast cancer drug

2026-04-30T18:15:59.000Z - 13 days ago

Guardant falls after FDA panel votes down AstraZeneca breast cancer drug

AZN GH

FDA panel votes against backing AstraZeneca's breast cancer drug

Thu, 30 Apr 2026 13:48:46 -0400 - 13 days ago

FDA panel votes against backing AstraZeneca's breast cancer drug

How AstraZeneca’s 17,000 AI-certified employees are helping it reach a ‘stretch goal’ of $80 billion in revenue

2026-04-30T12:35:25.000Z - 13 days ago

How AstraZeneca’s 17,000 AI-certified employees are helping it reach a ‘stretch goal’ of $80 billion in revenue

AstraZeneca upgraded to Buy from Hold at DZ Bank

2026-04-30T09:01:23.000Z - 13 days ago

AstraZeneca upgraded to Buy from Hold at DZ Bank

AZN

AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

2026-04-30T07:11:06.000Z - 13 days ago

AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Q1 2026 AstraZeneca PLC Earnings Call Transcript

2026-04-30T05:07:45.000Z - 13 days ago

Q1 2026 AstraZeneca PLC Earnings Call Transcript

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Wed, 29 Apr 2026 19:00:00 -0400 - 13 days ago

Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Big pharma can boost Britain: Labour must not let our flagship firms drift away, says RUTH SUNDERLAND

2026-04-29T21:00:49.000Z - 13 days ago

Big pharma can boost Britain: Labour must not let our flagship firms drift away, says RUTH SUNDERLAND

AstraZeneca (AZN) Announces £300 Million Investment in UK Following Strong Q1 Performance

2026-04-29T18:01:02.000Z - 14 days ago

AstraZeneca (AZN) Announces £300 Million Investment in UK Following Strong Q1 Performance

FTSE 100 closes lower as drugs firms GSK and AstraZeneca struggle

2026-04-29T16:17:59.000Z - 14 days ago

FTSE 100 closes lower as drugs firms GSK and AstraZeneca struggle

AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns

2026-04-29T15:31:38.000Z - 14 days ago

AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns

AstraZeneca Flexes Cancer Drugs Performance, Pipeline Strength

2026-04-29T14:27:12.000Z - 14 days ago

AstraZeneca Flexes Cancer Drugs Performance, Pipeline Strength

AstraZeneca Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:30 AM EDT - 14 days ago

AstraZeneca Earnings Call Transcript: Q1 2026

AstraZeneca makes surprise U-turn with £300m pharma investment

2026-04-29T12:15:51.000Z - 14 days ago

AstraZeneca makes surprise U-turn with £300m pharma investment

Astrazeneca tops expectations in the first quarter on strong cancer drug sales

2026-04-29T12:06:56.000Z - 14 days ago

Astrazeneca tops expectations in the first quarter on strong cancer drug sales

AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations

2026-04-29T11:30:47.000Z - 14 days ago

AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations

AstraZeneca (AZN) Forecasts Moderate Revenue Growth Through FY26

2026-04-29T11:28:10.000Z - 14 days ago

AstraZeneca (AZN) Forecasts Moderate Revenue Growth Through FY26

AstraZeneca (AZN) Reports Strong Q1 Revenue Growth

2026-04-29T11:27:46.000Z - 14 days ago

AstraZeneca (AZN) Reports Strong Q1 Revenue Growth

AstraZeneca to make $405 million investment in Britain, PM Starmer says

Wed, 29 Apr 2026 07:26:44 -0400 - 14 days ago

AstraZeneca to make $405 million investment in Britain, PM Starmer says

Shot in the arm for GSK and AstraZeneca from cancer drug sales

2026-04-29T11:21:47.000Z - 14 days ago

Shot in the arm for GSK and AstraZeneca from cancer drug sales

AstraZeneca reports Q1 core EPS $2.58, consensus $1.27

2026-04-29T09:41:54.000Z - 14 days ago

AstraZeneca reports Q1 core EPS $2.58, consensus $1.27

AstraZeneca sees FY26 core EPS up low double-digit percentage

2026-04-29T09:41:42.000Z - 14 days ago

AstraZeneca sees FY26 core EPS up low double-digit percentage

AstraZeneca Gets Revenue Boost From Cancer Drugs

Apr 29, 2026, 2:27 AM EDT - 14 days ago

AstraZeneca Gets Revenue Boost From Cancer Drugs

AstraZeneca beats profit expectations, keeps annual outlook unchanged

Apr 29, 2026, 2:05 AM EDT - 14 days ago

AstraZeneca beats profit expectations, keeps annual outlook unchanged

FDA Recruits AstraZeneca, Amgen in Bet on AI to Accelerate Drug Development

2026-04-28T19:10:29.000Z - 14 days ago

FDA Recruits AstraZeneca, Amgen in Bet on AI to Accelerate Drug Development

AMGN

Overhang should lift for Guardant after AstraZeneca AdCom, says Leerink

2026-04-28T18:45:21.000Z - 15 days ago

Overhang should lift for Guardant after AstraZeneca AdCom, says Leerink

GH

Guardant falls after FDA briefing documents for camizestrant

2026-04-28T18:10:20.000Z - 15 days ago

Guardant falls after FDA briefing documents for camizestrant

GH

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Apr 27, 2026, 7:00 AM EDT - 16 days ago

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Apr 21, 2026, 8:50 AM EDT - 22 days ago

Germany risks missing out on new drugs, AstraZeneca CEO tells paper

AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease

Apr 21, 2026, 2:26 AM EDT - 22 days ago

AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

Apr 20, 2026, 7:00 AM EDT - 23 days ago

Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups

Apr 20, 2026, 2:17 AM EDT - 23 days ago

AstraZeneca's tozorakimab delivers sharp reduction in COPD flare‑ups

Trump policies, China's biotech boom are ending Europe's pharma powerhouse era

Apr 11, 2026, 1:54 AM EDT - 4 weeks ago

Trump policies, China's biotech boom are ending Europe's pharma powerhouse era

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 5 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

ABBV AMGN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 5 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

NVO ABBV AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 5 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

ABBV AMGN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 5 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

NVO ABBV AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 5 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

ABBV AMGN BMY MRK

AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial

Apr 2, 2026, 6:47 AM EDT - 5 weeks ago

AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

Mar 31, 2026, 8:23 AM EDT - 6 weeks ago

AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results

AstraZeneca stock jumps as COPD drug trial win surprises market

Mar 27, 2026, 10:55 AM EDT - 6 weeks ago

AstraZeneca stock jumps as COPD drug trial win surprises market

AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

Mar 27, 2026, 8:54 AM EDT - 6 weeks ago

AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

Mar 27, 2026, 7:00 AM EDT - 6 weeks ago

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials

Mar 27, 2026, 3:51 AM EDT - 6 weeks ago

AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials

AstraZeneca drug reduces COPD flare ups in late-stage trials

Mar 27, 2026, 3:18 AM EDT - 6 weeks ago

AstraZeneca drug reduces COPD flare ups in late-stage trials

AstraZeneca says it will build cell therapy base, innovation centre in Shanghai

Mar 19, 2026, 12:52 AM EDT - 7 weeks ago

AstraZeneca says it will build cell therapy base, innovation centre in Shanghai

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

ABBV NVS SNY

AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer

Mar 16, 2026, 2:58 AM EDT - 2 months ago

AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer

Health Rounds: Death from dementia on the rise among people with type 2 diabetes

Mar 11, 2026, 7:28 AM EDT - 2 months ago

Health Rounds: Death from dementia on the rise among people with type 2 diabetes

LLY NVO

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

Mar 10, 2026, 8:30 AM EDT - 2 months ago

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

GLP-1 drugs protect against new or worsening addictions, large study shows

Mar 4, 2026, 6:36 PM EST - 2 months ago

GLP-1 drugs protect against new or worsening addictions, large study shows

LLY NVO

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

Feb 24, 2026, 6:33 AM EST - 2 months ago

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

Feb 11, 2026, 9:00 AM EST - 3 months ago

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

AstraZeneca results: FY and Q4 2025

Feb 10, 2026, 7:00 AM EST - 3 months ago

AstraZeneca results: FY and Q4 2025

AstraZeneca Forecasts Continued Growth on Pipeline Strength

Feb 10, 2026, 2:34 AM EST - 3 months ago

AstraZeneca Forecasts Continued Growth on Pipeline Strength

AstraZeneca profit climbs on cancer and heart drug demand

Feb 10, 2026, 2:24 AM EST - 3 months ago

AstraZeneca profit climbs on cancer and heart drug demand

Drugmaker AstraZeneca forecasts sales and profit growth in 2026

Feb 10, 2026, 2:06 AM EST - 3 months ago

Drugmaker AstraZeneca forecasts sales and profit growth in 2026

AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

Feb 3, 2026, 2:42 AM EST - 3 months ago

AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

US FDA rejects AstraZeneca's easier-to-use version of lupus therapy

Feb 3, 2026, 2:18 AM EST - 3 months ago

US FDA rejects AstraZeneca's easier-to-use version of lupus therapy

AstraZeneca begins trading on the New York Stock Exchange

Feb 2, 2026, 7:00 AM EST - 3 months ago

AstraZeneca begins trading on the New York Stock Exchange

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

Feb 1, 2026, 2:49 AM EST - 3 months ago

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

Jan 30, 2026, 2:51 AM EST - 3 months ago

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions

Jan 30, 2026, 2:15 AM EST - 3 months ago

World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

Jan 29, 2026, 8:35 PM EST - 3 months ago

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

AstraZeneca sets out $15 billion China investment during Starmer visit

Jan 29, 2026, 5:00 AM EST - 3 months ago

AstraZeneca sets out $15 billion China investment during Starmer visit

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

Jan 28, 2026, 4:01 PM EST - 3 months ago

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

HedgeFollow
HedgeFollow May. 13 at 5:11 PM
🔍 𝗝𝗣𝗺𝗼𝗿𝗴𝗮𝗻 13𝗙 𝗶𝘀 𝗢𝗨𝗧 🔎 Most notable position changes: 𝗔𝗱𝗱𝗲𝗱 60% 𝗺𝗼𝗿𝗲: $PG 𝗛𝗲𝗮𝘃𝗶𝗹𝘆 BOOSTED: $DG, $AZN 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 50%: $HOOD, $SHOP Procter & Gamble, Dollar General & Astrazeneca are good picks. JPmorgan is up 77% in the past 3 years Source: https://hedgefollow.com/funds/Jpmorgan+Chase+-And-+Co
0 · Reply
Charlie_Omaha
Charlie_Omaha May. 13 at 3:55 PM
$IOVA If any, Trump policies of Made in USA and Most Favored Nation rules make this an attractive candidate for $AZN $NVS $TAK as it counts as US plant and manufacturing, and accumulated debt as tax savings. Fred and Wayne are idiots.
0 · Reply
LandonCapital
LandonCapital May. 12 at 6:22 PM
$AZN https://landoncapital.net/meeting-the-standard-astrazeneca-drug-meets-primary-endpoint-in-rare-disease-trial/
0 · Reply
ApexEquityVault
ApexEquityVault May. 12 at 3:51 PM
High Confidence 🚨 $AZN 210 Call 6/18 at 0.65
0 · Reply
ApexEquityVault
ApexEquityVault May. 12 at 3:51 PM
$AZN 210 Call 6/18 at 0.65
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial May. 12 at 3:49 PM
$AZN 210 CALL 6/18 @ .65
0 · Reply
HedgeFollow
HedgeFollow May. 11 at 10:23 PM
🔍 𝗣𝗿𝗶𝗺𝗲𝗰𝗮𝗽 13𝗙 𝗷𝘂𝘀𝘁 𝗿𝗲𝗹𝗲𝗮𝘀𝗲𝗱! 🔎 Most notable trades Theofanis made last quarter: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 𝗕𝘂𝘆𝘀: $GTLB & $BA 𝗔𝗱𝗱𝗲𝗱 30-40% 𝗺𝗼𝗿𝗲: $ADBE & $ERIC 𝗥𝗲𝗱𝘂𝗰𝗲𝗱: $AZN 𝗦𝗢𝗟𝗗 𝗼𝘂𝘁: CRCL Theo's portfolio is up 92% in the past 3 years. Source: https://hedgefollow.com/funds/Primecap+Management
0 · Reply
biolover
biolover May. 11 at 2:40 PM
$VKTX $AZN had data on $LLY orfor copy in late 2025. Not promising when u wait 7 months and u are are a copy of already optimized but weak drug. AZN does not have anything competitive in obesity. The deal in China is all preclinical. Good luck. Management is preoccupied with combining oral GLP1 with fading farxiga But dont u need a molecule that works as a first step?
1 · Reply
Estimize
Estimize May. 11 at 12:06 PM
Wall St is expecting 2.49 EPS for $AZN Q2 [Reporting 07/27 BMO] http://www.estimize.com/intro/azn?chart=historical&metric_name=eps&utm_cont
0 · Reply
Quantumup
Quantumup May. 11 at 10:49 AM
Oppenheimer⬇️ $CRNX's PT to $84 from $87, reiterated at Outperform, and said: CRNX posted $10.7M in total revenue, above our/cons estimates of $7.0M/$8.5M as Palsonify's launch gathers steam. $AZN PFE $NVS IPSEY NBIS SPRB XERS Oppenheimer added—Phase 3 trial in carcinoid syndrome continues its enrollment, and atumelnant is moving along in its respective pivotal and Phase 2 trials in adult and pediatric CAH with a Phase 2/3 to soon begin in ACTH-dependent Cushing syndrome. We have our eye on CRN09682's initial clinical reveal in neuroendocrine tumors, which we believe will come toward year-end. Cash runway into 2030. Current levels may reflect a relative paucity of upcoming catalysts, but we believe today's buyers will be rewarded as CRNX's growing endocrine portfolio marks commercial and clinical success.
0 · Reply
GordoHLYK13
GordoHLYK13 May. 10 at 10:29 PM
$AIM They just dropped 50% ORR clinical data with $MRK Keytruda in advanced ovarian cancer… that’s exactly the type of data that attracts bigger financing opportunities. Small biotech offerings are common to bridge into larger partnerships, licensing, or Phase 3 expansion. If the data keeps delivering, this raise could end up looking tiny in hindsight. $AIM $MRK $AZN
0 · Reply
cloudhedge
cloudhedge May. 9 at 3:37 PM
$AZN is dropping some serious heat at ADA! The Phase 2b data for their oral GLP-1, aleniglipron, is officially out and the numbers are impressive. We're looking at mid-teens percentage weight loss in just 36 weeks. 📉 What’s even better is the tolerability profile—using a slower titration seems to be the secret sauce here to keep side effects in check. AstraZeneca is proving they can compete with the big players in the obesity space. Definitely a ticker to keep on the radar as this oral candidate moves forward. 💊
0 · Reply
NAWAF_26
NAWAF_26 May. 9 at 12:25 PM
$PFE $AZN $ABT $INDO Look at $MRNA Moderna (MRNA) has returned strongly to the spotlight as attention around emerging viruses continues to grow. With its advanced mRNA platform and rapid vaccine development capabilities, the company is once again being viewed as one of the top biotech growth plays in the market. The company has been working on mRNA research and vaccine development since 2023, and with the current strong buying momentum and rising trading volume, investors are paying close attention to the stock again. 📈 Current momentum looks very strong Heavy buying pressure Increasing media attention Vaccine sector gaining momentum again Clear bullish trend on the chart 🎯 Potential price targets $100 as a near-term target $200 as the next major target if momentum continues $300 as an extended target
0 · Reply
mikesterz7
mikesterz7 May. 9 at 1:15 AM
$NVAX $PFE $JNJ $MRNA $AZN The race to get a vaccine 😆🤣🤣🤣🤣
1 · Reply
DefenseMania
DefenseMania May. 7 at 4:11 AM
$AZN $BMY $EXEL $MRK Did u hear that lol BIG things ahead 😉
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 6 at 4:03 PM
$BCTX received FDA clearance to initiate a Bria-BRES+ clinical study: → Phase 1/2a in metastatic breast cancer → Next-gen immunotherapy platform → Designed to activate both innate + adaptive immune systems Why it matters https://www.globenewswire.com/news-release/2026/05/06/3288700/0/en/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer.html $BNTX $MRK $AZN #biotech #cancer
1 · Reply
trichomy
trichomy May. 5 at 3:23 PM
$INMB lots of hopeful investors looking at InmuneBio $SPY $AZN $QQQ
0 · Reply
MagisterofMarkets
MagisterofMarkets May. 5 at 11:34 AM
$AZN look at how much support there is at $180 over the last 6months
0 · Reply
Quantumup
Quantumup May. 4 at 5:46 PM
BofA⬆️ $INSM's PT to $214 (was $212),⬆️revenue/EPS estimates, reiterated at Buy, and said: Updated survey suggests Brinsupri launch still robust $AZN $MRK SNY - REGN LQDA UTHR Here's what else BofA had to say: https://x.com/Quantumup1/status/2051357205274693866?s=20
0 · Reply
Ventureville
Ventureville May. 4 at 1:24 PM
New validation out May 1. $BIOV.CSE $BVAXF adds MRI-backed evidence showing MVP-S combo activity in ovarian cancer models. That’s not just theory, imaging confirming immune-driven impact. Stack that with prior clinical signals and the DPX platform continues to show consistency. Big pharma like $MRK $BMY $AZN already built the checkpoint market. Smaller platforms with repeatable data tend to get noticed next.
0 · Reply
biolover
biolover May. 4 at 12:31 PM
One case is meaningless unless confirmed as no other reason to explain for $LLY orforglipron. But ALT imbalance was a repeated theme in all of $LLY ( higher dose ) , $GPCR and $AZN trials. $PFE killed danuglipron for a single case ? And CMO stated not even sure 100 % related. ? If this Lilly report is true then it is showing up at starter dose , which is possible when u give 20000 humans the drug and there in a potential for DDI. Again if true it is showing up much sooner than I thought. Could make oral peptide Co explode. like $VKTX has now with potentially two offerings with oral amylin peptide entering clinic
0 · Reply
Davidendz
Davidendz May. 1 at 5:28 PM
Immunotherapy momentum continuing to build, especially around checkpoint inhibitor combinations. $MRK (Keytruda) leading the space, with $BMY $AZN also competing in PD-1 / PD-L1. Now $BIOV.CSE $BVAXF adding more validation with MVP-S + checkpoint inhibitors + low-dose cyclophosphamide showing strong immune response signals in ovarian cancer. Durability stands out, responses lasting up to 3 years, and immune activation tied directly to disease control. This is where platform + combination therapy narratives start getting attention.
0 · Reply